Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456428 | 0.84 | KDM4E (0.49) | PDE4DKDM4EPOLBKMT2AMAPT | |
| SCHEMBL19158730 | 0.81 | PDE4D (0.59) | PDE4DKDM4EPOLBKMT2AMAPT | |
| SCHEMBL31367819 | 0.80 | PDE4D (0.73) | PDE4DKDM4EPOLBKMT2AMAPT | |
| SCHEMBL7814443 | 0.80 | PDE4D (0.58) | PDE4DKDM4EPOLBKMT2AMAPT | |
| SCHEMBL15555140 | 0.80 | KDM4E (0.51) | PDE4DKDM4EPOLBKMT2AMAPT | |
| SCHEMBL14190553 | 0.79 | PDE4D (0.56) | PDE4DKDM4EPOLBKMT2AMAPT | |
| SCHEMBL3945902 | 0.79 | HCAR2 (0.59) | PDE4DKDM4EPOLBKMT2AMAPT | |
| SCHEMBL2846088 | 0.79 | HCAR2 (0.59) | PDE4DKDM4EPOLBKMT2AMAPT | |
| SCHEMBL3078972 | 0.79 | PDE4D (0.56) | PDE4DKDM4EPOLBKMT2AMAPT | |
| SCHEMBL24906430 | 0.78 | KDM4E (0.43) | PDE4DKDM4EPOLBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867248-B1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-12-10 | — | — | EP | disclosed |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2025-04-10 | — | — | US | disclosed |
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| EP-4031552-B1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-06 | — | — | EP | disclosed |
| EP-4385979-A1 | MULTICYCLIC INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2024-06-19 | — | — | EP | disclosed |
| CN-115087652-B | Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein | 勃林格殷格翰国际有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-113272297-B | Pyrazole derivatives as H4 antagonist compounds | 赫普泰雅治疗有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-11851418-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-12-26 | — | — | US | disclosed |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-8952026-B2 | PRMT1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952026-B2 | PRMT1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952026-B2 | PRMT1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| WO-2014191896-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| WO-2014153090-A1 | PYRAZOLE DERIVATIVES ASPRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153090-A1 | PYRAZOLE DERIVATIVES ASPRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288140-A1 | PRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288140-A1 | PRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288140-A1 | PRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | HRH4, HRH3, HRH2 | PDE4D 1886/4885KDM4E 2803/4885POLB 4495/4885 |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | GPR139, GPR119, GPR39 | PDE4D 761/4885KDM4E 4254/4885POLB 4591/4885 |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | GPR139, GPR119, GPR39 | PDE4D 761/4885KDM4E 4254/4885POLB 4591/4885 |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | PKD1, PKD2, REN | PDE4D 114/4885KDM4E 2965/4885POLB 2315/4885 |
| US-11851418-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, CTRB2 | PDE4D 3713/4885KDM4E 1044/4885POLB 3917/4885 |
| US-20140288140-A1 | PRMT1 INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT6 | PDE4D 2484/4885KDM4E 70/4885POLB 1852/4885 |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HDAC3 | PDE4D 1786/4885KDM4E 2406/4885POLB 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.